USFDA approves expanded use of Bristol Myers Opdivo

The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer

Johnson & Johnson Vision Care receives USFDA approval for drug-eluting contact lens

Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category

DCGI approves Themis Medicare's Viralex for Covid-19 treatment

Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections

Bristol Myers Squibb’s application for Opdivo plus chemotherapy receives USFDA priority review

If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.

Daewoong completes combination therapy of antidiabetic drug Enavogliflozin

Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy

New data reinforces efficacy of Tezspire

These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod

If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.

Biohaven licenses Taldefgrobep Alfa from Bristol Myers Squibb

It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).

Sanofi and GSK to seek regulatory authorization for Covid-19 vaccine

100% efficacy against severe Covid-19 disease and hospitalizations

Prestige BioPharma’s Tuznue receives EU-GMP certification